Literature DB >> 16376322

Atherosclerosis and proteinase activation.

Clare M Dollery1, Peter Libby.   

Abstract

Rapidly accumulating evidence points to the matrix metalloproteinases (MMPs) as major molecular mediators of arterial diseases. Findings from human pathological specimens, animals, and cell and molecular biology implicate matrix metalloproteinases in all stages of atherosclerosis including lesion initiation and progression and ultimately in plaque complication and triggering of thrombosis. The complex interactions within the proteolytic cascade allow multiple levels of control over these functions. This review weighs the evidence for the role of MMPs in arterial biology with particular reference to their activation in the atherosclerotic plaque.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376322     DOI: 10.1016/j.cardiores.2005.11.003

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  80 in total

1.  Visceral adipose tissue-derived serine protease inhibitor prevents the development of monocrotaline-induced pulmonary arterial hypertension in rats.

Authors:  Yuzaburo Sakamoto; Satoshi Kameshima; Chiharu Kakuda; Yuta Okamura; Tomoko Kodama; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  Pflugers Arch       Date:  2017-08-03       Impact factor: 3.657

Review 2.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

3.  Molecular imaging of atherosclerosis: a progress report.

Authors:  Peter Libby; Matthias Nahrendorf; Ralph Weissleder
Journal:  Tex Heart Inst J       Date:  2010

Review 4.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

5.  Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.

Authors:  Valeria Arkadash; Gal Yosef; Jason Shirian; Itay Cohen; Yuval Horev; Moran Grossman; Irit Sagi; Evette S Radisky; Julia M Shifman; Niv Papo
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

6.  Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs.

Authors:  Yiannis S Chatzizisis; Aaron B Baker; Galina K Sukhova; Konstantinos C Koskinas; Michail I Papafaklis; Roy Beigel; Michael Jonas; Ahmet U Coskun; Benjamin V Stone; Charles Maynard; Guo-Ping Shi; Peter Libby; Charles L Feldman; Elazer R Edelman; Peter H Stone
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

7.  IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype.

Authors:  Jan H von der Thüsen; Keren S Borensztajn; Silvia Moimas; Sandra van Heiningen; Peter Teeling; Theo J C van Berkel; Erik A L Biessen
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

8.  Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages.

Authors:  Jason L Johnson; Graciela B Sala-Newby; Yasmin Ismail; Concepción M Aguilera; Andrew C Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

Review 9.  Caldesmon as a therapeutic target for proliferative vascular diseases.

Authors:  Chi-Ming Hai
Journal:  Mini Rev Med Chem       Date:  2008-10       Impact factor: 3.862

10.  Synthesis and in Vitro and in Vivo Evaluation of MMP-12 Selective Optical Probes.

Authors:  Thomas Bordenave; Marion Helle; Fabrice Beau; Dimitris Georgiadis; Livia Tepshi; Mylène Bernes; Yunpeng Ye; Laure Levenez; Enora Poquet; Hervé Nozach; Mahmoud Razavian; Jakub Toczek; Enrico A Stura; Vincent Dive; Mehran M Sadeghi; Laurent Devel
Journal:  Bioconjug Chem       Date:  2016-09-14       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.